Table 1 Baseline characteristics of study cohorts and number of first events of CHD and IS
Countries and studies | No. (men/women) | Age years Mean (range) | FPG* (mmol/l) | 2hPG* (mmol/l) | No. of events (men/women) | Maximum (Median) follow-up years | |
|---|---|---|---|---|---|---|---|
CHD | IS | ||||||
Finland | |||||||
East–West Study | 125/- | 76 (70–90) | 5.2 (0.04) | 5.4 (0.10) | 27/- | 24/- | 16.8 (10.4) |
FINRISK 1987 | 859/1006 | 53 (44–64) | 5.1 (0.01) | 5.5 (0.03) | 142/59 | 57/46 | 21.0 (20.8) |
FINRISK 1992 | 496/747 | 53 (44–64) | 5.2 (0.01) | 5.5 (0.03) | 32/18 | 8/11 | 16.0 (15.9) |
Helsinki Policemen Study | 578/- | 45 (31–69) | 5.7 (0.02) | 5.3 (0.05) | 141/- | 77/- | 36.8 (34.5) |
Oulu Study | 93/172 | 55 (55–55) | 5.4 (0.03) | 6.1 (0.07) | 4/4 | 5/5 | 17.3 (16.8) |
Vantaa Study | 120/168 | 65 (64–66) | 5.2 (0.03) | 6.2 (0.07) | 16/15 | 14/9 | 17.9 (17.3) |
Sweden | |||||||
Malmö Prevention Project | -/821 | 54 (48–57) | 5.5 (0.02) | 6.7 (0.04) | -/2 | -/16 | 20.0 (14.6) |
MONICA | 923/1002 | 45 (25–74) | 5.1 (0.01) | 5.3 (0.03) | 50/17 | 12/19 | 20.6 (16.4) |
ULSAM | 549/- | 71 (70–73) | 5.1 (0.02) | 5.5 (0.06) | 54/- | 38/- | 12.4 (10.2) |
Total | 3743/3916 | 53 (25–90) | 5.2 (0.01) | 5.6 (0.01) | 466/115 | 235/106 | 36.8 (16.4) |